2171 logo

CARsgen Therapeutics Holdings SZSC:2171 Stock Report

Last Price

HK$9.21

Market Cap

HK$5.1b

7D

1.4%

1Y

46.7%

Updated

31 Dec, 2024

Data

Company Financials +

CARsgen Therapeutics Holdings Limited

SZSC:2171 Stock Report

Market Cap: HK$5.1b

2171 Stock Overview

An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. More details

2171 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

CARsgen Therapeutics Holdings Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for CARsgen Therapeutics Holdings
Historical stock prices
Current Share PriceHK$9.21
52 Week HighHK$10.74
52 Week LowHK$2.48
Beta0.35
1 Month Change38.50%
3 Month Change93.89%
1 Year Change46.66%
3 Year Change-64.23%
5 Year Changen/a
Change since IPO-79.30%

Recent News & Updates

Recent updates

Shareholder Returns

2171HK BiotechsHK Market
7D1.4%-0.6%1.1%
1Y46.7%-13.5%17.6%

Return vs Industry: 2171 exceeded the Hong Kong Biotechs industry which returned -13.5% over the past year.

Return vs Market: 2171 exceeded the Hong Kong Market which returned 17.6% over the past year.

Price Volatility

Is 2171's price volatile compared to industry and market?
2171 volatility
2171 Average Weekly Movement21.0%
Biotechs Industry Average Movement10.6%
Market Average Movement8.5%
10% most volatile stocks in HK Market17.8%
10% least volatile stocks in HK Market3.9%

Stable Share Price: 2171's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2171's weekly volatility has increased from 14% to 21% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014477Zonghai Liwww.carsgen.com

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; CT011, which is in Phase I clinical trial for patients with Glypican-3 positive IIIa hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL). It is also developing CT0180 and CT0181, which targets Glypican-3 that is in Phase I clinical trial for the treatment of hepatocellular carcinoma.

CARsgen Therapeutics Holdings Limited Fundamentals Summary

How do CARsgen Therapeutics Holdings's earnings and revenue compare to its market cap?
2171 fundamental statistics
Market capHK$5.06b
Earnings (TTM)-HK$739.30m
Revenue (TTM)HK$6.75m

749.4x

P/S Ratio

-6.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2171 income statement (TTM)
RevenueCN¥6.34m
Cost of RevenueCN¥4.72m
Gross ProfitCN¥1.62m
Other ExpensesCN¥696.50m
Earnings-CN¥694.88m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.27
Gross Margin25.50%
Net Profit Margin-10,960.25%
Debt/Equity Ratio8.6%

How did 2171 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 02:29
End of Day Share Price 2024/12/31 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CARsgen Therapeutics Holdings Limited is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xiao Wei LinEverbright Securities Co. Ltd.
Ziyi ChenGoldman Sachs